Tags » Galt

Navy Vet: 'CA City Told Me to Take Down American Flag on D-Day'

Why does it cost $4,400 to file a petition to amend this law? Insanity.

From Fox News: A California Navy veteran and his wife expressed disbelief at the… 179 more words

United States

Overheard During Graduation Weekend

“It’s been getting some pretty bad reviews.”

Christopher’s description of his new, very short haircut.  Evidently his roommates Evan and Francis didn’t entirely approve.

“Just walk away.” 344 more words

NetworkNewsBreaks – Galectin Therapeutics, Inc. (NASDAQ: GALT) Receives Decision to Grant From Japanese Patent Office for GR-MD-02 Composition of Matter Patent

Galectin Therapeutics (NASDAQ: GALT) this morning said it has received a decision from the Japanese Patent Office to grant its patent application for “Composition of Novel Carbohydrate Drug for Treatment of Human Diseases.” Upon issuance, the patent will expand coverage of the company’s lead compound, GR-MD-02, to Japan through 2032. 330 more words

NetworkNewsWire Release

NetworkNewsBreaks – Galectin Therapeutics, Inc. (NASDAQ: GALT) Receives Decision to Grant From Japanese Patent Office for GR-MD-02 Composition of Matter Patent

Galectin Therapeutics (NASDAQ: GALT) this morning said it has received a decision from the Japanese Patent Office to grant its patent application for “Composition of Novel Carbohydrate Drug for Treatment of Human Diseases.” Upon issuance, the patent will expand coverage of the company’s lead compound, GR-MD-02, to Japan through 2032. 330 more words

NetworkNewsWire Release

How Fiber Alters Gut Immunity

Symbiosis: the interaction between two different organisms living in close, physical association and to the advantage of both.

A healthy gut, in a person enjoying a balanced diet, is full of friendly bacteria living with its human in symbiosis. 746 more words

Chronic Illness

NetworkNewsBreaks – Galectin Therapeutics (NASDAQ: GALT) Shares Hike on Positive Data from Phase 2a Clinical Trial of GR-MD-02

Shares of Galectin Therapeutics (NASDAQ: GALT) are up more than 8% this morning on the company’s report of positive results from an exploratory, phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. 403 more words

NetworkNewsWire Release

NetworkNewsBreaks – Galectin Therapeutics (NASDAQ: GALT) Shares Hike on Positive Data from Phase 2a Clinical Trial of GR-MD-02

Shares of Galectin Therapeutics (NASDAQ: GALT) are up more than 8% this morning on the company’s report of positive results from an exploratory, phase 2a clinical trial with GR-MD-02 in patients with moderate-to-severe plaque psoriasis. 403 more words

NetworkNewsWire Release